---
title: "Seaport Pops on Q1 Numbers"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289069193.md"
description: "Seaport Therapeutics (NASDAQ: SPTX) shares rose 2.8% to $16.91 following its Q1 2026 financial results. The company reported a net loss of $25.4 million, compared to $13.1 million in Q1 2025, with cash and investments totaling $212.6 million as of March 31. Subsequent to the quarter, Seaport completed an IPO raising $260 million gross proceeds. CEO Daphne Zohar highlighted clinical progress on GlyphAlloTM and GlyphAgoTM programs."
datetime: "2026-06-08T14:15:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289069193.md)
  - [en](https://longbridge.com/en/news/289069193.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289069193.md)
---

# Seaport Pops on Q1 Numbers

Seaport Therapeutics, Inc., (NASDAQ: SPTX) shares gained solidly Monday. The company, a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced financial results for the first quarter of 2026 and highlighted recent corporate and clinical progress.

Cash, cash equivalents, and investments totaled $212.6 million as of March 31. Subsequent to March 31, 2026, Seaport completed its IPO, in which the Company raised gross proceeds of an additional $260.0 million, before deducting underwriting discounts, commissions, and other offering expenses.

Net loss was $25.4 million for the first quarter of 2026, as compared to a net loss of $13.1 million for the first quarter of 2025.

“The first quarter of 2026 was filled with meaningful progress for Seaport, and we significantly advanced the clinical development of our lead GlyphAlloTM and GlyphAgoTM programs,” said CEO Daphne Zohar. “We previously reported data from the single-ascending dose and crossover portions of the Phase 1 proof-of-concept trial of GlyphAgoTM, which we believe substantially derisk future clinical development of the program.

“Today, we announced new multiple-ascending dose data from this trial, which further reinforce the ability of GlyphAgoTM to achieve therapeutic exposures of agomelatine at doses projected to avoid liver enzyme elevations. We continue to progress our potentially registration-enabling Phase 2b BUOY-1 trial of GlyphAlloTM and anticipate topline data from that trial in the first half of next year.”

SPTX shares jumped 47 cents, or 2.8%, to $16.91.

### Related Stocks

- [SPTX.US](https://longbridge.com/en/quote/SPTX.US.md)

## Related News & Research

- [Scorpio Gold pursues Nasdaq listing for American depositary shares](https://longbridge.com/en/news/293905134.md)
- [Scorpio Gold Moves to Launch Nasdaq ADS Listing to Expand U.S. Investor Reach](https://longbridge.com/en/news/293950190.md)
- [Vale updates financial events calendar for 2026](https://longbridge.com/en/news/294418484.md)
- [Pre-announcement of a financial report according to articles 114 - 117 WpHG](https://longbridge.com/en/news/294531814.md)
- [Bénéteau flags availability of new press release on H1 2026 sales update](https://longbridge.com/en/news/293954581.md)